KLA Corporation (KLAC)

Cyclical

FairStock Score: 60/100 — STEADY

Key Financials

Current Price$1,804.32
Market Cap$187.8B
P/E Ratio51.11
ROE94.98%
Dividend Yield0.48%
SectorTechnology

Strengths

Concerns

AI Analysis

KLA Corporation presents a fascinating paradox—a genuinely exceptional business trading at a price that defies Graham's margin of safety principle. Let me be direct: this is a compounder with legitimate competitive advantages. Their 100.73% ROE and 21.09% ROCE reflect a company that generates extraordinary returns on deployed capital. The semiconductor inspection equipment market is a duopoly essentially, and KLA's technological moat is formidable—customers cannot easily switch suppliers without massive disruption. Their latest quarter demonstrated 34.75% net margins and $3.2B in free cash flow, which is genuinely impressive. The Piotroski F-Score of 8/9 indicates fortress-like financial quality, and the Altman Z-Score of 11.24 suggests zero bankruptcy risk. However—and this is critical—the valuation is troubling. At a P/E of 43.67, EV/EBITDA of 127.68, and a Graham Number of $90.48 against a current price of $1,429.10, we're looking at a negative margin of safety of -1479%. The stock has traded from $551 to $1,693 in 52 weeks, suggesting speculation rather than rational valuation. The 0.7% FCF yield is anemic for a mature business. While I admire the business quality, I cannot recommend buying at these prices—not because the company isn't excellent, but because the price reflects perfection already baked in with no room for disappointment. This is a business to own, not at these multiples to buy.

Bull Case

KLA's duopoly position in mission-critical semiconductor inspection equipment positions it to capture decades of AI-driven chip manufacturing growth. As customers push to 2nm nodes and beyond, the complexity and value of inspection solutions increase, potentially justifying premium valuations and consistent 15-20% annual growth.

Bear Case

A semiconductor industry downturn could trigger sharp capex cuts, causing KLA's revenues to collapse 30-40% as historically demonstrated. At current valuations with minimal margin of safety, even modest disappointment in guidance could trigger a correction to $900-1100, destroying shareholder value for patient investors.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer